Hologic (NASDAQ:HOLX) Upgraded by Wall Street Zen to Buy Rating

Hologic (NASDAQ:HOLX) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday.

Several other analysts have also recently weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a report on Tuesday, May 27th. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and raised their target price for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Argus raised their price objective on shares of Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Finally, Mizuho set a $75.00 price objective on shares of Hologic in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $79.38.

Hologic Stock Performance

NASDAQ HOLX opened at $66.40 on Tuesday. Hologic has a 1 year low of $51.90 and a 1 year high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The stock has a market capitalization of $14.77 billion, a PE ratio of 27.55, a P/E/G ratio of 2.45 and a beta of 0.57. The company’s 50 day simple moving average is $66.66 and its two-hundred day simple moving average is $62.83.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the prior year, the company posted $1.06 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts predict that Hologic will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.88% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HOLX. Farther Finance Advisors LLC grew its stake in Hologic by 22.3% in the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider’s stock worth $113,000 after purchasing an additional 335 shares during the period. United Services Automobile Association purchased a new stake in shares of Hologic in the 1st quarter worth about $347,000. SG Americas Securities LLC grew its position in shares of Hologic by 116.6% in the 1st quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider’s stock worth $594,000 after buying an additional 5,172 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Hologic in the first quarter worth about $641,000. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider’s stock worth $1,980,000 after purchasing an additional 528 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.